Anika Therapeutics (ANIK) Total Non-Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has reported Total Non-Current Liabilities for 17 consecutive years, with $182.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 2.24% year-over-year to $182.7 million; the TTM figure through Jun 2026 stood at $182.7 million (down 2.24% YoY), while the FY2025 annual figure was $189.6 million, down 6.14% from the prior year.
• Total Non-Current Liabilities advanced to $182.7 million in Q2 2026 per ANIK's latest filing, from $178.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $353.5 million in Q2 2022 and bottomed at $178.7 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $262.8 million across 5 years, with a median of $262.8 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities climbed 2.11% — and 2024, when it retreated 29.64%.
• Anika Therapeutics' Total Non-Current Liabilities stood at $348.7 million in 2022, then retreated by 22.51% to $270.2 million in 2023, then slipped by 25.26% to $202.0 million in 2024, then declined by 6.14% to $189.6 million in 2025, then retreated by 3.6% to $182.7 million in 2026.
• Business Quant data shows ANIK's Total Non-Current Liabilities at $182.7 million in Q2 2026, $178.7 million in Q1 2026, and $189.6 million in Q4 2025.